Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the
field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues …

The therapeutic utility of antibodies and their derivatives is achieved by various means. The
FDA has approved several targeted antibodies that disrupt signaling of various growth factor …

Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …

Plants, marine organisms, and microorganisms have evolved complex chemical defense
and signaling systems that are designed to protect them from predators and provide other …

Gemtuzumab ozogamicin (GO), a monoclonal antibody used in the treatment of acute
myelogenous leukemia (AML) has been linked to the development of venoocclusive disease …

Antibody–drug conjugate (ADC) is a milestone in targeted cancer therapy that comprises of
monoclonal antibodies chemically linked to cytotoxic drugs. Internalization of ADC takes …

Antibody–drug conjugates (ADCs) are designed to specifically bind to and kill cells
expressing their target antigens. In addition to the obvious requirement of the presence of …

BACKGROUND: The development of antigen‐targeted therapies may provide additional
options to improve outcomes in children with acute myeloid leukemia (AML). The Children's …

Calicheamicin is a DNA-damaging agent that, following intracellular activation, binds to DNA
in the minor groove and introduces double-strand DNA breaks, leading to G2/M arrest and …

A large number of antibiotics are glycosides. In numerous cases the glycosidic residues are
crucial to their activity; sometimes, glycosylation only improves their pharmacokinetic …